According to our (Global Info Research) latest study, the global Ischemia Reperfusion Injury market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Reperfusion injury or reperfusion insult, sometimes called is chemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.
Global Ischemia Reperfusion Injury key players include Angion Biomedica, Catalyst Biosciences, Ischemix Inc, etc.
North America is the largest market, with a share about 50%, followed by Europe, and Japan, both have a share over 20 percent.
In terms of product, Phase 2 is the largest segment, with a share about 40%. And in terms of application, the largest application is Kidney Injury, followed by Heart Injury, Intestine Injury, etc.
On 2025-2-11 Global Info Research released【Global Ischemia Reperfusion Injury Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031】. This report includes an overview of the development of the Ischemia Reperfusion Injury industry chain, the market status of Consumer Electronics (Nickel-Zinc Ferrite Core, Mn-Zn Ferrite Core), Household Appliances (Nickel-Zinc Ferrite Core, Mn-Zn Ferrite Core), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Ischemia Reperfusion Injury.
Market segment by Type：Phase 1、Phase 2、Preclinical
Market segment by Application：Heart Injury、Kidney Injury、Intestine Injury、Other Injury
Major players covered： Angion Biomedica、Catalyst Biosciences、Ischemix Inc、Opsona Therapeutics、Pharming、TheraSource、Bolder Biotechnology、Corline Biomedical、Mifcortx、Balmes Transplantation、NovelMed Therapeutics、Hope Pharmaceuticals、Omeros Corp、Prothix、SBI Pharmaceuticals
Table of Contents
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Ischemia Reperfusion Injury by Type
1.3.1 Overview: Global Ischemia Reperfusion Injury Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Ischemia Reperfusion Injury Consumption Value Market Share by Type in 2024
1.3.3 Phase 1
1.3.4 Phase 2
1.3.5 Preclinical
1.4 Global Ischemia Reperfusion Injury Market by Application
1.4.1 Overview: Global Ischemia Reperfusion Injury Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Heart Injury
1.4.3 Kidney Injury
1.4.4 Intestine Injury
1.4.5 Other Injury
1.5 Global Ischemia Reperfusion Injury Market Size & Forecast
1.6 Global Ischemia Reperfusion Injury Market Size and Forecast by Region
1.6.1 Global Ischemia Reperfusion Injury Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Ischemia Reperfusion Injury Market Size by Region, (2020-2031)
1.6.3 North America Ischemia Reperfusion Injury Market Size and Prospect (2020-2031)
1.6.4 Europe Ischemia Reperfusion Injury Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Ischemia Reperfusion Injury Market Size and Prospect (2020-2031)
1.6.6 South America Ischemia Reperfusion Injury Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Ischemia Reperfusion Injury Market Size and Prospect (2020-2031)
2 Company Profiles
2.1 Angion Biomedica
2.1.1 Angion Biomedica Details
2.1.2 Angion Biomedica Major Business
2.1.3 Angion Biomedica Ischemia Reperfusion Injury Product and Solutions
2.1.4 Angion Biomedica Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Angion Biomedica Recent Developments and Future Plans
2.2 Catalyst Biosciences
2.2.1 Catalyst Biosciences Details
2.2.2 Catalyst Biosciences Major Business
2.2.3 Catalyst Biosciences Ischemia Reperfusion Injury Product and Solutions
2.2.4 Catalyst Biosciences Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Catalyst Biosciences Recent Developments and Future Plans
2.3 Ischemix Inc
2.3.1 Ischemix Inc Details
2.3.2 Ischemix Inc Major Business
2.3.3 Ischemix Inc Ischemia Reperfusion Injury Product and Solutions
2.3.4 Ischemix Inc Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Ischemix Inc Recent Developments and Future Plans
2.4 Opsona Therapeutics
2.4.1 Opsona Therapeutics Details
2.4.2 Opsona Therapeutics Major Business
2.4.3 Opsona Therapeutics Ischemia Reperfusion Injury Product and Solutions
2.4.4 Opsona Therapeutics Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Opsona Therapeutics Recent Developments and Future Plans
2.5 Pharming
2.5.1 Pharming Details
2.5.2 Pharming Major Business
2.5.3 Pharming Ischemia Reperfusion Injury Product and Solutions
2.5.4 Pharming Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Pharming Recent Developments and Future Plans
2.6 TheraSource
2.6.1 TheraSource Details
2.6.2 TheraSource Major Business
2.6.3 TheraSource Ischemia Reperfusion Injury Product and Solutions
2.6.4 TheraSource Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 TheraSource Recent Developments and Future Plans
2.7 Bolder Biotechnology
2.7.1 Bolder Biotechnology Details
2.7.2 Bolder Biotechnology Major Business
2.7.3 Bolder Biotechnology Ischemia Reperfusion Injury Product and Solutions
2.7.4 Bolder Biotechnology Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Bolder Biotechnology Recent Developments and Future Plans
2.8 Corline Biomedical
2.8.1 Corline Biomedical Details
2.8.2 Corline Biomedical Major Business
2.8.3 Corline Biomedical Ischemia Reperfusion Injury Product and Solutions
2.8.4 Corline Biomedical Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Corline Biomedical Recent Developments and Future Plans
2.9 Mifcortx
2.9.1 Mifcortx Details
2.9.2 Mifcortx Major Business
2.9.3 Mifcortx Ischemia Reperfusion Injury Product and Solutions
2.9.4 Mifcortx Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Mifcortx Recent Developments and Future Plans
2.10 Balmes Transplantation
2.10.1 Balmes Transplantation Details
2.10.2 Balmes Transplantation Major Business
2.10.3 Balmes Transplantation Ischemia Reperfusion Injury Product and Solutions
2.10.4 Balmes Transplantation Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Balmes Transplantation Recent Developments and Future Plans
2.11 NovelMed Therapeutics
2.11.1 NovelMed Therapeutics Details
2.11.2 NovelMed Therapeutics Major Business
2.11.3 NovelMed Therapeutics Ischemia Reperfusion Injury Product and Solutions
2.11.4 NovelMed Therapeutics Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 NovelMed Therapeutics Recent Developments and Future Plans
2.12 Hope Pharmaceuticals
2.12.1 Hope Pharmaceuticals Details
2.12.2 Hope Pharmaceuticals Major Business
2.12.3 Hope Pharmaceuticals Ischemia Reperfusion Injury Product and Solutions
2.12.4 Hope Pharmaceuticals Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Hope Pharmaceuticals Recent Developments and Future Plans
2.13 Omeros Corp
2.13.1 Omeros Corp Details
2.13.2 Omeros Corp Major Business
2.13.3 Omeros Corp Ischemia Reperfusion Injury Product and Solutions
2.13.4 Omeros Corp Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Omeros Corp Recent Developments and Future Plans
2.14 Prothix
2.14.1 Prothix Details
2.14.2 Prothix Major Business
2.14.3 Prothix Ischemia Reperfusion Injury Product and Solutions
2.14.4 Prothix Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 Prothix Recent Developments and Future Plans
2.15 SBI Pharmaceuticals
2.15.1 SBI Pharmaceuticals Details
2.15.2 SBI Pharmaceuticals Major Business
2.15.3 SBI Pharmaceuticals Ischemia Reperfusion Injury Product and Solutions
2.15.4 SBI Pharmaceuticals Ischemia Reperfusion Injury Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 SBI Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Ischemia Reperfusion Injury Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Ischemia Reperfusion Injury by Company Revenue
3.2.2 Top 3 Ischemia Reperfusion Injury Players Market Share in 2024
3.2.3 Top 6 Ischemia Reperfusion Injury Players Market Share in 2024
3.3 Ischemia Reperfusion Injury Market: Overall Company Footprint Analysis
3.3.1 Ischemia Reperfusion Injury Market: Region Footprint
3.3.2 Ischemia Reperfusion Injury Market: Company Product Type Footprint
3.3.3 Ischemia Reperfusion Injury Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Ischemia Reperfusion Injury Consumption Value and Market Share by Type (2020-2025)
4.2 Global Ischemia Reperfusion Injury Market Forecast by Type (2026-2031)
5 Market Size Segment by Application
5.1 Global Ischemia Reperfusion Injury Consumption Value Market Share by Application (2020-2025)
5.2 Global Ischemia Reperfusion Injury Market Forecast by Application (2026-2031)
6 North America
6.1 North America Ischemia Reperfusion Injury Consumption Value by Type (2020-2031)
6.2 North America Ischemia Reperfusion Injury Market Size by Application (2020-2031)
6.3 North America Ischemia Reperfusion Injury Market Size by Country
6.3.1 North America Ischemia Reperfusion Injury Consumption Value by Country (2020-2031)
6.3.2 United States Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
6.3.3 Canada Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
6.3.4 Mexico Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
7 Europe
7.1 Europe Ischemia Reperfusion Injury Consumption Value by Type (2020-2031)
7.2 Europe Ischemia Reperfusion Injury Consumption Value by Application (2020-2031)
7.3 Europe Ischemia Reperfusion Injury Market Size by Country
7.3.1 Europe Ischemia Reperfusion Injury Consumption Value by Country (2020-2031)
7.3.2 Germany Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
7.3.3 France Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
7.3.5 Russia Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
7.3.6 Italy Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Ischemia Reperfusion Injury Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Ischemia Reperfusion Injury Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Ischemia Reperfusion Injury Market Size by Region
8.3.1 Asia-Pacific Ischemia Reperfusion Injury Consumption Value by Region (2020-2031)
8.3.2 China Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
8.3.3 Japan Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
8.3.4 South Korea Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
8.3.5 India Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
8.3.7 Australia Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
9 South America
9.1 South America Ischemia Reperfusion Injury Consumption Value by Type (2020-2031)
9.2 South America Ischemia Reperfusion Injury Consumption Value by Application (2020-2031)
9.3 South America Ischemia Reperfusion Injury Market Size by Country
9.3.1 South America Ischemia Reperfusion Injury Consumption Value by Country (2020-2031)
9.3.2 Brazil Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
9.3.3 Argentina Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Ischemia Reperfusion Injury Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Ischemia Reperfusion Injury Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Ischemia Reperfusion Injury Market Size by Country
10.3.1 Middle East & Africa Ischemia Reperfusion Injury Consumption Value by Country (2020-2031)
10.3.2 Turkey Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
10.3.4 UAE Ischemia Reperfusion Injury Market Size and Forecast (2020-2031)
11 Market Dynamics
11.1 Ischemia Reperfusion Injury Market Drivers
11.2 Ischemia Reperfusion Injury Market Restraints
11.3 Ischemia Reperfusion Injury Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Ischemia Reperfusion Injury Industry Chain
12.2 Ischemia Reperfusion Injury Upstream Analysis
12.3 Ischemia Reperfusion Injury Midstream Analysis
12.4 Ischemia Reperfusion Injury Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.